Source comparison
MOTS-c for Insulin Resistance Research: Mechanism Comparison
MOTS-c Mitochondrial-to-nuclear signaling; GLUT4 upregulation Direct, LKB1-independent No. Bypasses insulin receptor Yes. Originates from mitochondrial genome Phase I/II human trials; robust rodent data Unique retrograde signaling pathway with metabolic flexib
This comparison does not assign a generated winner or score.
- MOTS-c
- Mitochondrial-to-nuclear signaling; GLUT4 upregulation
- Direct, LKB1-independent
- No. Bypasses insulin receptor
- Yes. Originates from mitochondrial genome
- Phase I/II human trials; robust rodent data
- Unique retrograde signaling pathway with metabolic flexibility benefits not seen in conventional sensitizers
- Metformin
- LKB1-AMPK activation; hepatic gluconeogenesis suppression
- Indirect, LKB1-dependent
- No. But improves insulin-mediated glucose disposal
- Limited. Primarily cytoplasmic effects
- Decades of clinical use; established first-line therapy
- Effective but hepatic-focused; GI side effects common; mechanism doesn't address mitochondrial dysfunction
- Thiazolidinediones
- PPARγ agonism; adipocyte differentiation
- No
- Yes. Enhances insulin receptor signaling
- FDA-approved for type 2 diabetes
- Effective insulin sensitizer but causes weight gain, fluid retention, and increased fracture risk
- GLP-1 Agonists
- Incretin receptor activation; beta-cell preservation
- Indirect through improved insulin secretion
- Yes. Insulin-dependent effects
- Extensive clinical use; weight loss benefits
- Addresses insulin secretion, not cellular insulin resistance; requires functional beta cells
- The most significant differentiation: MOTS-c is the only intervention in this table that originates from mitochondrial genetic material and functions as a retrograde signaling molecule. Conventional insulin sensitizers work downstream of mitochondrial dysfunction. MOTS-c addresses mitochondrial signaling capacity directly.